Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Has 19 Applications Remaining With User Fees In 2004: 7 NMEs, 1 BLA

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

With seven first-cycle new molecular entities with user fee deadlines in November and December, FDA could surpass the total number of new molecular entities approved in 2003.

You may also be interested in...



Yamanouchi Vaprisol “approvable”

Yamanouchi's Vaprisol (conivaptan) is "approvable" Nov. 30; FDA is requesting additional safety data for the hyponatremia agent. Discussions with the agency are ongoing but the company has not specified a timeframe for complete response. A September review by FDA's Endocrinologic & Metabolic Drugs Advisory Committee was cancelled. Vaprisol qualified for a priority review, but Yamanouchi opted for a standard review to allow time for the advisory committee to take place (1Pharmaceutical Approvals Monthly Nov. 1, 2004, p. 3)...

Yamanouchi Vaprisol “approvable”

Yamanouchi's Vaprisol (conivaptan) is "approvable" Nov. 30; FDA is requesting additional safety data for the hyponatremia agent. Discussions with the agency are ongoing but the company has not specified a timeframe for complete response. A September review by FDA's Endocrinologic & Metabolic Drugs Advisory Committee was cancelled. Vaprisol qualified for a priority review, but Yamanouchi opted for a standard review to allow time for the advisory committee to take place (1Pharmaceutical Approvals Monthly Nov. 1, 2004, p. 3)...

Duloxetine Drug Interactions Are Issue For Yentreve, But Not For Cymbalta

Review documents for Cymbalta note a difference in opinion regarding the significance of drug interactions between FDA’s review divisions for the two duloxetine indications – major depressive disorder and stress urinary incontinence (under the trade name Yentreve).

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS002702

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel